These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21819808)

  • 1. [Evidence-based therapeutic drug monitoring for indinavir].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):239-46. PubMed ID: 21819808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence-based therapeutic drug monitoring of lopinavir].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):231-8. PubMed ID: 21819807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):239-46. PubMed ID: 27393204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidence-based therapeutic drug monitoring of atazanavir].
    Solas C; Muret P;
    Therapie; 2011; 66(3):213-9. PubMed ID: 21819805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based therapeutic drug monitoring for saquinavir].
    Muret P; Solas C;
    Therapie; 2011; 66(3):207-12. PubMed ID: 21819804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
    Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
    Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
    J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
    Cressey TR; Urien S; Hirt D; Halue G; Techapornroong M; Bowonwatanuwong C; Leenasirimakul P; Treluyer JM; Jourdain G; Lallemant M;
    Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V; Hocht C; Mangano A; Niselman V; Mariño Hernández E; Cáceres Guido P; Mecikovsky D; Bellusci C; Bologna R; Sen L; Rubio MC; Bramuglia GF
    Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Telenti A; Biollaz J; Buclin T
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3226-32. PubMed ID: 15328077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
    Wasmuth JC; Rodermann E; Voigt E; Vogel M; Lauenroth-Mai E; Jessen A; Burger D; Rockstroh JK
    Eur J Med Res; 2007 Jul; 12(7):289-94. PubMed ID: 17933700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
    Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JM; Phanuphak P; Cooper DA; Burger DM
    J Antimicrob Chemother; 2006 Jun; 57(6):1161-7. PubMed ID: 16595641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
    Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P
    Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.